$LTRN
Lantern Pharma Inc. Stock $ltrn

$ltrn Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000149315224018422 Filed on May 09, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.520M	$1.481M	$1.733M
YoY Change	-6.88%	-14.54%	23.27%
% of Gross Profit
Research & Development	$3.889M	$4.251M	$2.553M
YoY Change	9.29%	66.51%	-4.03%
% of Gross Profit
Depreciation & Amortization	$4.260K	$4.061K	$3.418K
YoY Change	21.37%	18.81%	71.76%
% of Gross Profit
Operating Expenses	$5.408M	$5.732M	$4.286M
YoY Change	4.2%	33.73%	5.41%
Operating Profit	-$5.408M	-$5.732M	-$4.286M
YoY Change	4.2%	33.73%	5.41%
Interest Expense	$188.7K	$201.0K	$133.8K
YoY Change	60.13%	50.21%	496.7%
% of Operating Profit
Other Income/Expense, Net	$260.3K	$90.24K	$284.7K
YoY Change	-20.17%	-68.31%	-465.97%
Pretax Income	-$4.960M	-$5.441M	-$3.868M
YoY Change	4.49%	40.67%	-6.16%
Income Tax
% Of Pretax Income
Net Earnings	-$4.960M	-$5.441M	-$3.868M
YoY Change	4.49%	40.67%	-6.16%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.46	-$0.51	-$0.36
Diluted Earnings Per Share	-$0.46	-$0.51	-$0.36
COMMON SHARES
Basic Shares Outstanding	10.76M shares	10.74M shares	10.86M shares
Diluted Shares Outstanding	10.76M shares	10.74M shares	10.86M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$33.26M	$38.36M	$51.54M
YoY Change	-30.63%	-25.58%	-20.97%
Cash & Equivalents	$12.98M	$18.36M	$32.48M
Short-Term Investments	$20.29M	$20.00M	$19.06M
Other Short-Term Assets	$2.029M	$1.113M	$3.628M
YoY Change	-34.38%	-69.32%	48.26%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$35.29M	$39.47M	$55.17M
YoY Change	-30.86%	-28.45%	-18.47%
LONG-TERM ASSETS
Property, Plant & Equipment	$50.29K	$50.28K	$53.47K
YoY Change	0.68%	-5.95%	-70.34%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$32.02K	$25.87K	$32.97K
YoY Change	23.76%	-21.54%	-94.1%
Total Long-Term Assets	$295.4K	$263.4K	$341.8K
YoY Change	-23.1%	-22.94%	-53.78%
TOTAL ASSETS
Total Short-Term Assets	$35.29M	$39.47M	$55.17M
Total Long-Term Assets	$295.4K	$263.4K	$341.8K
Total Assets	$35.59M	$39.73M	$55.51M
YoY Change	-30.8%	-28.42%	-18.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.437M	$3.775M	$2.674M
YoY Change	55.52%	41.21%	-8.4%
Accrued Expenses	$164.0K	$178.0K	$119.6K
YoY Change	0.52%	48.87%	-22.95%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.601M	$3.953M	$2.793M
YoY Change	52.55%	41.54%	-9.13%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$54.69K	$15.56K	$140.6K
YoY Change	-63.71%	-88.94%	957.37%
Total Long-Term Liabilities	$54.69K	$15.56K	$140.6K
YoY Change	-63.71%	-88.94%	957.37%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.601M	$3.953M	$2.793M
Total Long-Term Liabilities	$54.69K	$15.56K	$140.6K
Total Liabilities	$4.655M	$3.969M	$2.934M
YoY Change	47.01%	35.28%	-4.97%
SHAREHOLDERS EQUITY
Retained Earnings	-$65.64M	-$60.69M	-$43.15M
YoY Change	37.05%	40.64%
Common Stock	$1.076K	$1.076K	$1.086K
YoY Change	-1.01%	-0.92%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$30.93M	$35.77M	$52.58M
YoY Change
Total Liabilities & Shareholders Equity	$35.59M	$39.73M	$55.51M
YoY Change	-30.8%	-28.42%	-18.85%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	-$4.960M	-$5.441M	-$3.868M
YoY Change	4.49%	40.67%	-6.16%
Depreciation, Depletion And Amortization	$4.260K	$4.061K	$3.418K
YoY Change	21.37%	18.81%	71.76%
Cash From Operating Activities	-$5.191M	-$3.069M	-$3.757M
YoY Change	44.51%	-18.33%	12.9%
INVESTING ACTIVITIES
Capital Expenditures	$4.260K	$2.217K	$8.876K
YoY Change		-75.02%
Acquisitions
YoY Change
Other Investing Activities	-$197.8K	-$554.0K	-$952.0K
YoY Change	-56.74%	-41.81%	-639.32%
Cash From Investing Activities	-$202.1K	-$556.2K	-$960.9K
YoY Change	-55.81%	-42.12%	-644.34%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	$54.72K
YoY Change
NET CHANGE
Cash From Operating Activities	-5.191M	-$3.069M	-$3.757M
Cash From Investing Activities	-202.1K	-$556.2K	-$960.9K
Cash From Financing Activities	0.000	$54.72K
Net Change In Cash	-5.393M	-$3.580M	-$4.723M
YoY Change	33.18%	-24.21%	-11.45%
FREE CASH FLOW
Cash From Operating Activities	-$5.191M	-$3.069M	-$3.757M
Capital Expenditures	$4.260K	$2.217K	$8.876K
Free Cash Flow	-$5.195M	-$3.071M	-$3.766M
YoY Change	44.63%	-18.46%	13.17%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001763950
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets		usd
CY2023Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2024Q1	us-gaap	Restricted Cash RestrictedCash		usd
CY2024Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2024Q1	LTRN	Remeasurement Of Operating Lease Rightofuse Asset And Operating Lease Liability RemeasurementOfOperatingLeaseRightofuseAssetAndOperatingLeaseLiability		usd
CY2023Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost		usd
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity Registrant Name EntityRegistrantName	Lantern Pharma Inc.
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q1	dei	Entity File Number EntityFileNumber	001-39318
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-3973463
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	1920 McKinney Avenue
CY2024Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	7th Floor
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Dallas
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	75201
CY2024Q1	dei	City Area Code CityAreaCode	(972)
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	277-1136
CY2024Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value
CY2024Q1	dei	Trading Symbol TradingSymbol	LTRN
CY2024Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2024Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	10758805	shares
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18357944	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21937749	usd
CY2024Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	19999910	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	19364923	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1113007	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2038653	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	39470861	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	43341325	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	50283	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	52127	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	187211	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	228295	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	25869	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	25869	usd
CY2024Q1	us-gaap	Assets Assets	39734224	usd
CY2023Q4	us-gaap	Assets Assets	43647616	usd
CY2024Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3775423	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2505211	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	178023	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	172975	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	3953446	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2678186	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	15561	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	61496	usd
CY2024Q1	us-gaap	Liabilities Liabilities	3969007	usd
CY2023Q4	us-gaap	Liabilities Liabilities	2739682	usd
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	25000000	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10758805	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10758805	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10721192	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10721192	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	1076	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1072	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	96447495	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	96258726	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1860	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-107460	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-60685214	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-55244404	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	35765217	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	40907934	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	39734224	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	43647616	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1481215	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1733321	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4250786	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2552947	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	5732001	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	4286268	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5732001	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4286268	usd
CY2024Q1	us-gaap	Interest Income Other InterestIncomeOther	200950	usd
CY2023Q1	us-gaap	Interest Income Other InterestIncomeOther	133782	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	90241	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	284721	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-5440810	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-3867765	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.51
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.51
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.36
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.36
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10742797	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10742797	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10857040	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10857040	shares
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-3867765	usd
CY2024Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	43946	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	50773	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	65374	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	20936	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	109320	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	71709	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5331490	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3796056	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	56038024	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	333530	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-3867765	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	71709	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	52575498	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	40907934	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	40907934	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	54716	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	134057	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-5440810	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	109320	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	35765217	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	35765217	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-5440810	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4061	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3418	usd
CY2024Q1	us-gaap	Other Noncash Expense OtherNoncashExpense	41084	usd
CY2023Q1	us-gaap	Other Noncash Expense OtherNoncashExpense	40025	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	134057	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	333530	usd
CY2024Q1	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	34069	usd
CY2023Q1	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	60018	usd
CY2024Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-99338	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-38194	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	-929	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	-37960	usd
CY2024Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	3950	usd
CY2023Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	42150	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-901017	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	117638	usd
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10721192	shares
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1270707	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-67300	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-40887	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-40332	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	15080	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3068523	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3757156	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2217	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8876	usd
CY2024Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	6012284	usd
CY2023Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	3102001	usd
CY2024Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	5458333	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	2150000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-556168	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-960877	usd
CY2024Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	54716	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	54716	usd
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-9830	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-4983	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3579805	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4723016	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	21937749	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	37742966	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	18357944	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	33019950	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18357944	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	32478770	usd
CY2023Q1	us-gaap	Restricted Cash RestrictedCash	541180	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	18357944	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	33019950	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	48811	usd
CY2023Q1	LTRN	Remeasurement Of Operating Lease Rightofuse Asset And Operating Lease Liability RemeasurementOfOperatingLeaseRightofuseAssetAndOperatingLeaseLiability	198847	usd
CY2024Q1	us-gaap	Debt Securities Unrealized Gain Loss DebtSecuritiesUnrealizedGainLoss	43946	usd
CY2023Q1	us-gaap	Debt Securities Unrealized Gain Loss DebtSecuritiesUnrealizedGainLoss	50773	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-5441000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-3868000	usd
CY2024Q1	LTRN	Working Capital WorkingCapital	35517000	usd
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	45000	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_849_eus-gaap--UseOfEstimates_zDpoQqunJ4U" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zdr254tZxSDc">Use of Estimates and Assumptions</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The significant areas of estimation include determining research and development accruals, the inputs in determining the fair value of equity-based awards and warrants issued, the inputs in determining present value of lease payments, and determining the fair value of marketable securities. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zDizNRtHWrm8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zP6dIE066Xsa">Risks and Uncertainties</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company operates in an industry that is subject to intense competition, government regulation and rapid technological change. Operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory, and other risks, including the potential risk of business failure.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our marketable securities have had and may in the future have their market value fluctuate due to rises or falls in interest rates. While we believe our cash, cash equivalents and marketable securities do not contain excessive risk, we cannot provide absolute assurance that in the future our investments will not be subject to adverse changes in market value. In addition, we maintain significant amounts of cash and cash equivalents at one or more financial institutions that are federally insured. Interest bearing and non-interest bearing accounts we hold at these banking institutions are guaranteed by the Federal Deposit Insurance Corporation (“FDIC”) up to $<span id="xdx_907_eus-gaap--CashFDICInsuredAmount_iI_c20240331__srt--RangeAxis__srt--MaximumMember_zYK5SDs0cuuj" title="Cash FDIC insured amount">250,000</span> per depositor, per FDIC-insured bank, per ownership category. Substantially all of our cash balances held at banking institutions at March 31, 2024 are in excess of FDIC coverage.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	16687000	usd
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	20881000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	187211	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	228295	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	178023	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	172975	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	15561	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	61496	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	193584	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	234471	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	139578	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	62448	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	202026	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	8442	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	193584	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	178023	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	15561	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	228295	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	234471	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	41084	usd
CY2024Q1	LTRN	Operating Lease Liability Amortization Expense OperatingLeaseLiabilityAmortizationExpense	40887	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	187211	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	193584	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y29D
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y14D
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0736	pure
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0744	pure
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	42000	usd
CY2024Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	4500	usd
CY2024Q1	us-gaap	Lease Cost LeaseCost	49500	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	42000	usd
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	45000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	42000	usd
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	25000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	25000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10758805	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10758805	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10721192	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1091196	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.11
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	20000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.70
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	33904	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	6.12
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1077292	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.14
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	900945	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	6.23
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	134057	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	333530	usd
CY2024Q1	LTRN	Available For Sale Securities Amortized Costs AvailableForSaleSecuritiesAmortizedCosts	20504805	usd
CY2024Q1	LTRN	Marketable Securities Unrealized Gains MarketableSecuritiesUnrealizedGains	1175	usd
CY2024Q1	LTRN	Marketable Securities Unrealized Losses MarketableSecuritiesUnrealizedLosses	506070	usd
CY2024Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	19999910	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue	14133428	usd
CY2024Q1	LTRN	Available For Sale Securities Debt Maturities Rolling Year One Through Two Fair Value AvailableForSaleSecuritiesDebtMaturitiesRollingYearOneThroughTwoFairValue	290082	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	14423510	usd
CY2024Q1	LTRN	Debt Securities Available For Sale Fair Value Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss	6156129	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	10282	usd
CY2024Q1	LTRN	Debt Securities Available For Sale Continuous Fair Value Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss	10504770	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	495788	usd
CY2024Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet	30385594	usd
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1158788	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1273044	shares

Files In Submission

Name	View Source	Status
ltrn-20240331_cal.xml	Edgar Link	unprocessable
0001493152-24-018422-index-headers.html	Edgar Link	pending
0001493152-24-018422-index.html	Edgar Link	pending
0001493152-24-018422.txt	Edgar Link	pending
0001493152-24-018422-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
ltrn-20240331.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
ltrn-20240331_def.xml	Edgar Link	unprocessable
ltrn-20240331_lab.xml	Edgar Link	unprocessable
ltrn-20240331_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LTRN
Lantern Pharma Inc. Stock $ltrn

2024 Q2 Form 10-Q Financial Statement

#000149315224018422 Filed on May 09, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LTRN Lantern Pharma Inc. Stock $ltrn

2024 Q2 Form 10-Q Financial Statement

#000149315224018422 Filed on May 09, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LTRN
Lantern Pharma Inc. Stock $ltrn